First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

HI Hurwitz (1), HC Pitot (2), DC Smith (3), J Brill (4), G Vuagniaux (5), E Rouits (5), C Zanna (5), M Sorensen (4)

Presented at ASCO 2014, Chicago, USA

1. Duke University, Durham, USA
2. Mayo Clinic, Rochester, USA
3. University of Michigan, Ann Arbor, USA
4. Ascenta Therapeutics, Malvern, USA
5. Debiopharm International SA, Lausanne, Switzerland